XML 30 R20.htm IDEA: XBRL DOCUMENT
v3.25.1

Legal Settlements and Loss Contingencies | 3 Months Ended
--- | ---
Mar. 31, 2025
Legal Settlements and Loss Contingencies | NOTE 9 – Legal settlements and loss contingencies: In the first quarter of 2025, Teva recorded expenses of $86 million in legal settlements and loss contingencies, compared to expenses of $106 million in the first quarter of 2024. Expenses in the first quarter of 2025 were mainly related to an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments). Expenses in the first quarter of 2024 were mainly related to an update to the estimated settlement provision of the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments), as well as an update to the estimated provision for the U.S. DOJ patient assistance program litigation. See note 10. As of March 31, 2025 and December 31, 2024, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $4,877 million and $4,881 million, respectively.

X
- Definition The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContent + Details
Name: | us-gaap_LegalMattersAndContingenciesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration